Oculis Trial Shows Potential for Optical Neuroprotective Therapy

Exec Edge

01-07

By Karen Roman

Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.

Oculis also said it received the Investigational New Drug application clearance from the FDA.

“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.

Contact:

Exec Edge

Editor@executives-edge.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2501296629"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501296629\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501296629?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 06:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2501296629","market":"us","top_or_hot":-1,"title":"Oculis Trial Shows Potential for Optical Neuroprotective Therapy","media":"Exec Edge","content":"<html><body><p><img height=\"642\" src=\"https://s1.yimg.com/uu/api/res/1.2/jw5indjOBvrJRftkXBFzUw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a613ca440c02807ea06bbed3db5751bc\" width=\"1536\"/></p>\n<p>By Karen Roman</p>\n<p><a href=\"https://laohu8.com/S/OCS\">Oculis</a> Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.</p>\n<p>Oculis also said it received the Investigational New Drug application clearance from the FDA.</p>\n<p>“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.</p>\n<p>Contact:</p>\n<div>\nExec Edge\n</div>\n<div>\n<p>Editor@executives-edge.com</p>\n</div></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oculis Trial Shows Potential for Optical Neuroprotective Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOculis Trial Shows Potential for Optical Neuroprotective Therapy\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Exec Edge</strong><span class=\"h-time small\">2025-01-07 06:30</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p><img height=\"642\" src=\"https://s1.yimg.com/uu/api/res/1.2/jw5indjOBvrJRftkXBFzUw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a613ca440c02807ea06bbed3db5751bc\" width=\"1536\"/></p>\n<p>By Karen Roman</p>\n<p><a href=\"https://laohu8.com/S/OCS\">Oculis</a> Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.</p>\n<p>Oculis also said it received the Investigational New Drug application clearance from the FDA.</p>\n<p>“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.</p>\n<p>Contact:</p>\n<div>\nExec Edge\n</div>\n<div>\n<p>Editor@executives-edge.com</p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/oculis-trial-shows-potential-optical-223042372.html\">Exec Edge</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCS","symbol_name":"Oculis","start_time":0,"source_url":"https://finance.yahoo.com/news/oculis-trial-shows-potential-optical-223042372.html","article_id":"2501296629","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501296629","pubTimestamp":1736202642,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Oculis Holding AG  said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.Oculis also said it received the Investigational New Drug application clearance from the FDA.“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” saidRiad Sherif, Oculis’ CEO.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCS":"Oculis","BK4007":"制药","OCSAW":"OCULIS HOLDING AG C/WTS 02/03/2028 (TO PUR ORD)","OCC":"Optical Cable Corporation","BK4020":"通信设备"},"translate_title":"Oculis试验显示视神经保护疗法的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC":1,"OCS":1,"OCSAW":0.9},"content_text":"By Karen Roman\nOculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.\nOculis also said it received the Investigational New Drug application clearance from the FDA.\n“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.\nContact:\n\nExec Edge\n\n\nEditor@executives-edge.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}